NEW YORK (GenomeWeb News) – Cellular Dynamics International today said that it has signed a deal to supply the Nestlé Institute of Health Sciences with its iCell and MyCell product lines.
The iCell portfolio includes cardiomyocytes, neurons, hepatocytes, endothelial cells, and other cell types in development, while the MyCell line includes cell products manufactured from donor samples using iPSC technology to make stem cells or differentiated cells from any individual.
"The ongoing work and this long-term supply agreement with NIHS demonstrate the utility and broad applicability of our iCell and MyCell Products," CDI CEO Bob Palay said in a statement. "This supply agreement with NIHS adds nutritional research as yet another field that will benefit from CDI's products and expertise."
Financial and other terms of the agreement were not disclosed.